EP1503629A1 - Yogourt fermente a cultures multiples - Google Patents
Yogourt fermente a cultures multiplesInfo
- Publication number
- EP1503629A1 EP1503629A1 EP03721220A EP03721220A EP1503629A1 EP 1503629 A1 EP1503629 A1 EP 1503629A1 EP 03721220 A EP03721220 A EP 03721220A EP 03721220 A EP03721220 A EP 03721220A EP 1503629 A1 EP1503629 A1 EP 1503629A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- yogurt
- fermented
- fermented milk
- milk product
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013618 yogurt Nutrition 0.000 title claims abstract description 134
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 174
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 66
- 235000014121 butter Nutrition 0.000 claims abstract description 35
- 235000014048 cultured milk product Nutrition 0.000 claims abstract description 33
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 33
- 239000004310 lactic acid Substances 0.000 claims abstract description 33
- 241000186660 Lactobacillus Species 0.000 claims abstract description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 26
- 239000008101 lactose Substances 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims abstract description 17
- 229930182830 galactose Natural products 0.000 claims abstract description 17
- 108010059881 Lactase Proteins 0.000 claims abstract description 9
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 9
- 150000002632 lipids Chemical class 0.000 claims abstract description 9
- 239000006041 probiotic Substances 0.000 claims abstract description 9
- 230000000529 probiotic effect Effects 0.000 claims abstract description 9
- 235000018291 probiotics Nutrition 0.000 claims abstract description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 8
- 102100026189 Beta-galactosidase Human genes 0.000 claims abstract description 8
- 235000013351 cheese Nutrition 0.000 claims abstract description 8
- 229940116108 lactase Drugs 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 230000002950 deficient Effects 0.000 claims abstract description 7
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 7
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 6
- 230000030833 cell death Effects 0.000 claims abstract description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 6
- 235000013376 functional food Nutrition 0.000 claims abstract description 5
- 235000013336 milk Nutrition 0.000 claims description 25
- 239000008267 milk Substances 0.000 claims description 25
- 210000004080 milk Anatomy 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 230000001839 systemic circulation Effects 0.000 claims description 4
- 241000049865 Ecdyonurus helveticus Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 38
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 23
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 210000002919 epithelial cell Anatomy 0.000 description 14
- 230000009467 reduction Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 7
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 5
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 240000002605 Lactobacillus helveticus Species 0.000 description 4
- 230000000923 atherogenic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 235000015205 orange juice Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 244000253911 Saccharomyces fragilis Species 0.000 description 3
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 108010001539 D-lactate dehydrogenase Proteins 0.000 description 2
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000451942 Abutilon sonneratianum Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 108010027805 Azocoll Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- KVZLHPXEUGJPAH-QRLADXQJSA-N C([C@H](O)C)(=O)O.C([C@H](O)C)(=O)O Chemical compound C([C@H](O)C)(=O)O.C([C@H](O)C)(=O)O KVZLHPXEUGJPAH-QRLADXQJSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000521553 Pichia fermentans Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003988 headspace gas chromatography Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000020603 homogenised milk Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 235000020190 lactose-free milk Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 230000000444 normolipidemic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 235000021193 standardized breakfast Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C15/00—Butter; Butter preparations; Making thereof
- A23C15/12—Butter preparations
- A23C15/123—Addition of microorganisms or cultured milk products; Addition of enzymes; Addition of starter cultures other than destillates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0325—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using yeasts, alone or in combination with lactic acid bacteria or with fungi, without using other bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
Definitions
- the present invention relates to a fermented milk product such as yogurt, butter or cheese comprising bacteria from the Lactobacillus species and yeast and a lactose content of less than 10 g/1 and a lactic acid content of at least 0,2 weight %. It also relates to a unique two-step method for producing fermented yogurt with Lactobacillus bacteria and yeast.
- a pharmaceutical or probiotic composition comprising the fermented milk product, use of such a fermented milk product for the production of a pharmaceutical for lowering of plasma triglycerides and lipids, for hampering cell death and fatty-liver caused by the consumption of alcohol, for profylax and treatment of atherosclerosis and coronary heart disease and for profylax and treatment of lactase and galactase deficient individuals. It also concerns a symbiotic or functional food product comprising the fermented milk product
- Alcohol at least in industrialised countries is perhaps the most common cause of liver cirrhosis. Alcohol is a hepatotoxin that affects mitochondrial and microsomal functions, where part of the hepatotoxic effects could be attributed to enzymatic oxidation of ethanol to acetaldehyde.
- the ethanol metabolism has furthermore been implicated in increased mobilisation of free fatty acids, diminished utilisation of triglycerides, decreased oxidation of fatty acids, increased esterification and reduced lipoprotein excretion (Niemela et al., 1998). Free radicals generated from oxidative stress can remove electrons from unsaturated fatty acids resulting in lipid radicals.
- the lipid radicals can react with oxygen to form lipid peroxide radicals which, in turn, interact with other fatty acids, thereby creating a chain reaction of lipid peroxidation.
- Such chain reactions may generate biologically active compounds, such as molecules that cause widening or narrowing of blood vessels, thereby increasing the risk of cardiovascular disease (Ponnappa et al., 2000).
- Lactobacillus cultures possess low lipase activity.
- the lipids in fermented yogurt product are partially degraded and thus the digestibility of hydrolysed fermented yogurt fat is higher.
- Blanc et al., 1973 there is a 2.5-fold increase in free acids in natural yogurt compared to milk.
- Rasic et al., 1978 concluded that the lipase activity processed by lactic acid bacteria in yogurt favourably influences the dietetic value of the final fermented product.
- a milk product that has been fermented in a first step with lactobacilli and in a second step, preferably after dilution(s) with lactobacilli and yeast comprises a low content of lactose and a high content of lactic acid compared to ordinary yogurt.
- Yogurt and butter and cheese produced thereof have beneficial effects on pharmacokinetics of alcohol.
- these products protect epithelial cells against exposure to alcohol, reduce the blood alcohol concentration (BAC) and lower the plasma lipid content.
- USP 4 034 115 and EP 0 122 104 disclose a two and three step respectively fermentation process of milk with lactobacilli in order to break down lactose in milk.
- No yeast is used and there is no information about any effect on pharmacokinetics of alcohol.
- Tarhana is a fermented product comprising yogurt and yeast but also cereal and vegetables such as tomatoes, onions, green pepper etc., Department of Food Engineering, Trakya University, Agriculture Faculty of Tekirdag, Turkey, 2000. Summary of the invention
- the present invention relates to a fermented milk product such as yogurt, butter or cheese comprising bacteria from the Lactobacillus species and yeast and having a galactose content of less than 1,2 g/1, a lactose content of less than 1,2 g/1, and lactic acid content of at least 0.2 weight %. It also relates to a two step method for producing fermented yogurt with Lactobacillus bacteria and yeast.
- a pharmaceutical or probiotic composition comprising a fermented milk product, comprising bacteria from the Lactobacillus species and yeast, use of a fermented milk product for the production of a pharmaceutical for lowering of plasma triglycerides and lipids, for hampering cell death and fatty-liver caused by the consumption of alcohol, for profylax and treatment of atherosclerosis and coronary heart disease and for profylax and treatment of lactase and galactase deficient individuals. It also concerns a symbiotic or functional food product comprising the fermented milk product
- ADH bacterial alcohol-dehydrogenase
- ADH acetaldehyd- dehydrogenase
- ADH acetaldehyd- dehydrogenase
- fermented yogurt suspension or lactic acid to human epithelial cells diminished ethanol-induced cell-death (Example 2).
- the fermented yogurt end product reduces ethanol (Example 4) and triglycerides levels in serum.
- the fermented yogurt products cause delayed uptake of ethanol in the gastrointestinal (GI) tract and a reduction in systemic ethanol levels.
- the regular intake of the fermented products may attenuate development of fatty-liver caused by extensive consumption of ethanol and in addition, stabilise Atherogenic Index (Al, explained in page 20), which would be beneficial for prevention of atherosclerosis and coronary heart disease.
- the products according to the present invention are novel preventive and therapeutic agents for combating disorders caused by excessive alcohol intake, and/or elevated blood-lipids levels. They can be used for the reduction of total plasma cholesterol and serum ethanol concentration thus lowering the incidence of coronary heart disease and fatty liver disease, respectively.
- the present invention relates to a fermented milk product comprising bacteria from the Lactobacillus species and yeast and a galactose content of less than 1,2 g/1, a lactose content of less than 1,2 g/1, and lactic acid content of at least 0.2 weight %.
- the galactose content is less than 1,2 g/1 (0,12%) and the lactose content less than 0,4 (0,04%) g/1 and most preferred the galactose content is less than 0,4 g/1 (0,04%) and the lactose content of less than 0,4 g/1 (0,04%).
- the pH of the milk product is below 4,5, especially below 4,1 and most preferred below 3,5 and especially 3,4.
- the yeast may be any yeast such as Kluyveromyces thermotolerans, Pichia fermentans and Saccharomyces cerevisiae.
- yeast is chosen from Kluyveromyces marxianus/Hansen Van der Walt, k ⁇ fir 14, DSM 14502.
- the Lactobacillus species may be chosen from the genus Lactobacillus and Streptococcus, preferably L. helveticus (AD4550/01 DSM 14492) and L. acidophilus (Lb. 67 DSM 14499).
- the fermented milk product according to the invention may be any dairy product such as yogurt, butter, cottage cheese or cheese.
- the invention also relates to a method for producing a fermented yogurt, characterised in that milk is heated, Lactobacillus bacteria are added and the bacterial suspension is incubated at 25-30, preferably at 37°C for 2-24, preferably 12 hours in normal atmosphere, the yogurt produced is preferably diluted with water and additional Lactobacillus bacteria and in addition, yeast is added and the suspension is incubated at 15-25 °C, preferably at room temperature for 1- 15, days, preferably 7 days in a closed system.
- Fermentation is here defined as processes that release energy from carbohydrates but do not require oxygen.
- a multi-cultural fermented yogurt is made using at least one preferably at least two Lactobacillus strains in combination with at least one yeast strain by processes that utilise the disaccharide carbohydrate lactose, which is naturally present in yogurt.
- the Lactobacillus strains and yeast strain respectively may be the same or different strains.
- the milk that is used as starting product, may be any type of milk, such as natural and untreated milk, pasteurised and homogenised milk of low fat type, standard type or with the natural content of fat.
- the milk is warmed to 25-120°C, preferably 35-110 °C, especially 85-105°C and most preferred to 100°C for at least 5 minutes, preferably at least 10 minutes and especially for about 15 minutes.
- a culture of bacteria is added.
- the bacterial suspension is then incubated at 25-50 °C, preferably 37°C for at least 5 hours, preferably 7-20 hours and most preferred 12 hours in normal atmosphere.
- 1 volume yogurt may be added to 0,2-10 volumes of water, preferably to 0,5-6 volumes of water, especially to 1-4 volumes of water and most preferably to 2 volumes of water, i.e. a dilution of 1/1.2-1/11 vol./vol., preferably 1/1,5-1/7 vol./ vol., especially 1/2-1/5 vol./vol. and most preferred 1/3 vol./vol.
- Additional Lactobacilli bacterial cells diluted 1 : 1000 and yeast diluted 1 : 10000 of cultivated cell cultures are added.
- the suspension is then incubated at room temperature (20-30°C) for at least 24 hours, preferably 2-15 days, preferably one week in a closed system.
- the dilution with water that is a dilution step without the addition of nurturance (such as milk-product) will drive the fermentative processes further, which promotes the formation of beneficially substances and effects as described below, where the unique combination of low lactose and galactose continuance qualitative characteristic of the products.
- nurturance such as milk-product
- the end product comprises about 15%, especially 5-10% living lactobacillus strains. It is believed that this is due to the degradation of both lactose and galactose.
- the product may be kept in room temperature for more than a year and still keep its qualities.
- any additives such as stabilising, thickening and/or flavouring agent may be added.
- sodium chloride e.g. 0.08% w/v NaCl
- thickener hydroxymethyl cellulose may be used.
- stabilisers gelatine, vegetable gums, carboxymethyl cellulose, locust bean, guar and seaweed gums like alginates and carrageenans.
- the multi-cultured yogurt is then further fermented for about one week. Then the churning cream in form of butter may be separated from the fermented suspension by shaking at 30° for 24 hours.
- the butter consists of 95% fat and live bacteria and yeast.
- the invention relates to any type of cheese such as cottage cheese made from the multicultural milk product of the invention according to well established methods in industry.
- the content of lactose in the product is less than 10 g/1, preferably less than 5 g/1, especially less than 2 g/1 such as less than lg/1 and especially less than 0,8 g/1.
- the lactose content in yogurt and lactose free milk is between 10-30 g/1 respectively 1-10 g/1 (according to the Swedish national food administration).
- the lactose content is less than 1 g/1 and preferably less than 0.05 g/1, especially less than 0.4 g/1 and most preferably less than 0.4 g/1.
- the lactic acid content of the multi-cultural product is at least 0.2 weight % preferably at least 0.3 weight %, such as at least 0.4 weight %.
- the content is typically around 0.3-0.6, especially 0.4-0.5 weight %. This is more than in the casual yogurt, which contains D(-) lactic acid (0.05 g/lOOg) and L(+) lactic acid (0.07 g/lOOg) in total 0.12 weight %, compared to the fermented yogurt which contain higher amount especially of the D (-) isomer, around 0.5 g/lOOg).
- the invention also relates to a pharmaceutical or probiotic composition
- a pharmaceutical or probiotic composition comprising a fermented milk product, comprising bacteria from the Lactobacillus species and yeast having a lactose content of less than 1,2 g/1 and especially less than 0,8 g/1 and a lactic acid content of at least 0.2 weight %.
- the invention also relates to a pharmaceutical or probiotic composition
- a pharmaceutical or probiotic composition comprising a fermented milk product, comprising bacteria from the Lactobacillus species and yeast having a galactose content of less than 1,2 g/1, especially less than 0.4 g/1.
- One aspect of the invention is the use of a fermented milk product according to the invention for the production of a pharmaceutical for lowering of plasma triglycerides and lipids.
- Another aspect of the invention is the use of a fermented milk product according the invention for the production of a pharmaceutical for hampering cell death, especially caused by the consumption of alcohol.
- a further aspect of the invention is the use of a fermented milk product according to the invention for the production of a pharmaceutical for hampering fatty-liver, especially caused by the consumption of alcohol.
- Still another aspect of the invention is the use of a fermented milk product according the invention for the production of a pharmaceutical for profylax and treatment of atherosclerosis and coronary heart disease.
- the invention also covers the use of a fermented milk product according the invention for the production of a pharmaceutical for profylax and treatment of lactase and galactase deficient individuals.
- the invention also concerns a symbiotic or functional food product comprising the fermented milk product
- FIG 1A Analysis of the effect of ethanol and fermented yogurt in a dilution series on human epithelial cells. Spots staples indicate the effect of ethanol on epithelial cells and sphere staples indicate the protective effect of fermented yogurt-supernatant (v/v). The error bars indicate the percentage error amount ( ⁇ 5%). FY; Fermented Yogurt.
- Figure IB Analysis of the protective effect of lactic acid mixed with a dilution series of alcohol on human epithelial cells. Spots staples indicate the protective effect of ethanol on epithelial cells and outlined diamond indicate the effect of 0.4 lactic acid (v/v) in the presence of ethanol with increasing dilution. The error bars indicate the percentage error amount ( ⁇ 5%).
- LA Lactic Acid.
- Figure lC Analysis of the protective effects of fermented yogurt mixed with a dilution series of alcohol on human epithelial. Spots staples indicate the effect of ethanol on epithelial cells and horizontal brick indicate the protective effect of fermented yogurt- supernatant (v/v) in the presence of ethanol with increasing dilution. The error bars indicate the percentage error amount ( ⁇ 5%). FY; Fermented Yogurt.
- FIG 2 A The protective effect of the fermented yogurt on the blood alcohol concentration (BAC), in one healthy man after oral administration of 62.5 ml ethanol (40% v/v) diluted with 62.5 ml orange juice. 45 minutes after intake of alcohol, the blood samples was obtained.
- the Figure shows the corresponding concentrations of serum ethanol after drinking of different quantities of fermented yogurt. Dashed vertical staples indicate the negative control (300 ml milk) and shingle staples show different intake of fermented yogurt in ml. The error bars indicate the percentage error amount ( ⁇ 2.5%). Al; Alcohol, FY; Fermented yogurt.
- FIG. 2B Serum alcohol profile in three healthy subjects (I, II and III), who consumed 62.5 ml ethanol (40% v/v) diluted with 62.5 ml orange juice, together with 300 ml fermented yogurt in exactly 30 minutes after standard breakfast. 45 minutes after drinking end, samples of blood were obtained.
- the spot staples indicate serum alcohol profile in combination with milk (300 ml, as control), and shingle staples are corresponded alcohol profile in combination with fermented yogurt.
- the error bars indicate the percentage error amount ( ⁇ 2.5%). FY; Fermented Yogurt.
- FIG. 3 Serum alcohol profile in two healthy subjects (I and II), who drank 250 ml ethanol (40% v/v) in two different occasions in exactly 3 hours immediately after dinner. In the first occasion 500 ml milk and in the second occasion 500 ml fermented yogurt (shingle staples), after end of drinking. After eight hours after drinking end, samples of blood were obtained. The error bars indicate the percentage error amount ( ⁇ 2.5%). Al; Alcohol, FY; Fermented Yogurt.
- FIG. 4 Serum-triglyceride concentration profile for five healthy volunteers (I, II, III, IV and V) before and after treatment with fermented yogurt/butter.
- One person, who had normal diet during experiment (I) was used as control, and two persons (II and III) consumed 45 g fermented butter diurnal.
- IV and V represent the persons who consumed one litre- fermented yogurt.
- Spot staples indicate triglyceride concentration before and shingle staples after treatment.
- Spot staples indicate Al before and shingle staples after treatment.
- Lactobacillus and growth conditions For production and fermentation of yogurt a bacterium of the Lactobacillus species, preferably Lactobacillus acidophilus (Lb 67 DSM 14499), Lactobacillus helveticus (AD4550/01 DSM 14492) and yeast (Kluyveromyces marxianus/Hansen Nan der Walt, k ⁇ fir 14, DSM 14502,), were grown in MRS broth (Difco) or Rogosa plates, in 37°C with gentle shaking for 24 hours.
- Lactobacillus acidophilus Lb 67 DSM 14499
- Lactobacillus helveticus AD4550/01 DSM 14492
- yeast Karluyveromyces marxianus/Hansen Nan der Walt, k ⁇ fir 14, DSM 14502
- Example 2 Fermented yogurt protects epithelial cells against exposure to alcohol
- the epithelial cell cultures were human epithelial cell culture (KB-line, CCL 17, Flow Laboratories, Glasgow, UK) grown at 37°C in the presence of 5% C0 2 .
- KB cells were grown in Eagle minimum essential medium (E-MEM) supplemented with 20,000 U/l penicillin, 100 ⁇ g/1 streptomycin, 0.2 mg/1 L-glutamine and 10% fetal calf serum were added. Then, cell culture medium was enriched with non-essential amino acids (10 ml/1 from a stock solution). The growth medium was changed every 48 h.
- the KB cell cultures in the cytotoxicity experiments were in their third to eighth passage used as the target cells.
- the epithelial cell lineage KB was established and used to investigate the possible cell protective effects of sterile filtrated fermented yogurt on alcohol exposure in vitro. Fermentation results in conversion of the lactose into lactic acid and thereby contributes to acidity (pH 4.9) of the product. Pre-digestive and enzymatic activities by Lactobacillus and yeast strains in combination with low pH could possibly have negative effects on cell-growth.
- Figure 1 A the epithelial cells were exposed to either alcohol or fermented yogurt in dilution series and cell viability was analysed. There was no significantly reduction in viable cells due to exposure to fermented yogurt only.
- fermented yogurt contains several bio-active compounds, with inhibitory effects on alcohol.
- the presence of lactic acid in fermented yogurt is desirable since it acts as a natural preservative and thereby contribute to the biological safety of the product, therefore, the bio-protective effects of lactic acid against alcohol was analysed.
- the results (Fig IB) demonstrate that lactic acid in low concentration (0.4, pH 4.9) protects the epithelial cell viability during alcohol exposure.
- the original suspension of fermented and edible yogurt was evaluated for protective effects facing alcohol exposure.
- Fig 1 C the epithelial cells were exposed to alcohol together with fermented yogurt product.
- the results show congruity as in Fig B, where toxicity of alcohol is negligible in presence of lactic acid.
- ethanol possibly due toesterification with lactic acid (Fig IB) or constituents of fermented yogurt such as amino acids glycine and alanine became undetectable in the blood as free ethanol.
- the similar effects by amino acids has been described by Widmark, 1933, Widmark, 1936; Neymark and Widmark, 1941).
- Long-term fermentation of a multi-cultured yogurt cause low pH due to lactic acid and consequently, lysis of the bacterial cells. Thereby, high levels of endogenous ADH and ALDH enzymes are released in to the Gl-tract and available for inactivation of ethanol.
- Example 3 Blood alcohol concentration (BAC) in one individual after oral administration of ethanol together with different volumes of fermented yogurt
- Venous blood samples obtained from an indwelling catheter were used for determination of blood ethanol.
- the blood was drawn into 5 ml Vacutainer tubes containing Sodium fluoride (20 mg, NaF) and heparin (143 units). Aliquots of blood-serum (100 ⁇ l) were removed and diluted 11-fold with n-propanol (8 mg/1) as an internal standard.
- the serum and internal standard were injected into head space sampling vials (22 ml), which were immediately made air-tight with rubber stoppers and crimped-on aluminium caps.
- head space sampling vials 22 ml
- a glass column packed with Carbopack C (0.2% Carbowax 1500 on Carbopack 80-100 mesh) was used as the stationary phase.
- Figure 2A shows blood alcohol concentrations (BACs) from a series of experiments.
- the volunteer consumed 62.5 ml of ethanol (40% v/v, diluted to 20% v/v with orange juice) supplemented with milk or fermented yogurt.
- the volunteer drank an identical volume of ethanol but supplemented with 300 ml of regular milk, a mixture which did not confer any reduction in BAC compared to the positive control (Fig 2A, milk).
- fermented yogurt contains high level of lactic acid, which can esterfy ethanol. Ethanol has here shown to undergo esterification with lactic acid (Fig IB) or constituents of fermented yogurt such as amino acids glycine and alanine and therefore become undetectable in the blood as free ethanol.
- Fig IB lactic acid
- constituents of fermented yogurt such as amino acids glycine and alanine and therefore become undetectable in the blood as free ethanol.
- long-term fermentation of a multi-cultured yogurt cause low pH by lactic acid and consequently, lysis of the bacterial cells. Thus, high levels of endogenous ADH and ALDH enzymes are released.
- Example 4 The effect of fermented yogurt on BAC in three volunteers
- the protective effect of pre-treatment of fermented yogurt was analysed in three volunteers.
- the higher level of fermented yogurt was chosen, i.e. the 300 ml volume, and ingested with ethanol during a 45-minut test period.
- Three healthy male and female students with a mean age 25.3 yr. (range 18-35), a mean body weight of 60.3 kg (range 50-68 kg), and a mean high of 169.3 cm (range 158-180 cm) were recruited as non-paid volunteers. All subjects were non-smokers except for one and in good health. They were not taking any medication at the time. Each subject participated in four experimental sessions with at least one day apart.
- a small dose of alcohol (0.35-0.5 g/kg) was administered after the subjects had eaten a standardised breakfast.
- the ethanol (40% v/v) was diluted with orange juice to give a 20% v/v cocktail and consumed with 300 ml-commercial yogurt diluted with water (milk consistence) during 30 minutes period after breakfast. 15 minutes and 8 h later, a venous blood samples were drawn.
- the subjects consumed the same volume and doses of ethanol, but with 300 ml of fermented yogurt instead of milk.
- the meals were prepared from commonly available foodstuffs used for breakfast in Sweden and the individual components were chosen to contain low proportions of fat (20%) and protein (36%) and carbohydrate (46%), providing approximately 500 kcal of energy.
- Figure 2B shows the individual BACs after treatment with fermented yogurt.
- the yogurt pre-treatment had conferred substantial reductions in BAC levels, ranging from 58% to almost 80% in reduction, with a mean reduction of 69% in BAC.
- Example 5 The effect of delayed administration of fermented yogurt on BAC in two volunteer persons
- the effect of delayed ingestion of the fermented yogurt product on BAC was also investigated.
- the two volunteer persons first ingested 250 ml alcohol (40% v/v) during a three-hour period, following dinner.
- the volunteer persons were given 500 ml of regular milk in a first session, respectively 500 ml of fermented yogurt product in a second (identical) session.
- the BAC values were measured after an additional 8 hours period.
- the results demonstrate that also delayed administration and ingestion of the fermented yogurt product affects the pharmacokinetics of ethanol absorption.
- the results suggest that the active components of the fermented yogurt product exhibit alcohol reducing and cleansing properties also when the alcohol has been absorbed from the Gl-tract to the blood and systemic circulation.
- Fig 3 The results from Fig 3 suggest that alcohol can be metabolised and thus reduced from blood in the first passage metabolism (FPM), because of the induction of ADH and ALDH enzymes to the gastrointestinal epithelial lining by fermented yogurt. Therefore, the remained alcohol in stomach does not entrance into the systemic circulation. Alternatively, lactic acid might be absorbed to the systemic circulation and cause esterification of alcohol.
- FPM first passage metabolism
- Example 6 The content of lactose and galactose in fermented yogurt product
- the content of galactose and lactose in the fermented yogurt produced in Example 1 were analysed by use of ion-chromatography with electrochemical detection. The analysis was performed by AnalyCen Nordic AB, 404 29 Gothenburg, Sweden. The analyse method was done with high-performance liquid chromatography (A206:21, HPLC).
- Lactase and galactase seem to be present in active forms since the level lactose and galactose were significantly decreased in fermented yogurt compared with casual yogurt.
- the concentrations of these carbohydrates were less than 0.4 g/L by using ion chromatography with electrochemical detection.
- galactosemia a rare inherited inborn error of metabolism
- free galactose may cause intolerance.
- We also analysed the content of lactose and galactose In the fermented yogurt product the results showed 90% reduction of lactose and galactose which could be important factor for better tolerating fermented yogurt by lactase or galactase deficient individual.
- Example 7 The content of lactic acid optical isomers (L + and D -) in fermented yogurt product
- Lactic acid in fermented yogurt occurs in two optical isomers, L(+) and D(-).
- L(+) and D(-) the content of L(+) and D(-) isomers were analysed by using spectophotometery analysis.
- the casual yogurt contain D(-) lactic acid (0.05 g/lOOg) and L(+) lactic acid (0.07 g/lOOg) compared to the fermented yogurt which contain higher amount of D (-) isomer, (0.47 g/lOOg).
- D-lactate dehydrogenase D-lactic acid
- NAD nicotinamide-adenine dinucleotide
- L-LDH L-Lactate dehydrogenase
- Example 8 Composition of fermented butter
- the multi-cultured yogurt was fermented for one week.
- Butter was made by churning of liquid fermented yogurt until the fatty globules of butter separated from the suspension.
- the churning cream in form of butter was separated from the fermented suspension by shaking at 30°Cfor 24 hours.
- the butter constituency was analysed by gas- chromatography with capillary column and flame ionisation's detector (AnalyCen Nordic AB, 404 29 Gothenburg, Sweden).
- CFU Colony Forming Units
- a serial dilution was made to estimate the number of living bacteria in the fermented yogurt and butter products. 1 ml samples were transferred to a tube containing 9 ml of sterile water and a serial dilution was made and inoculated on selective ROGOSA-plates for Lactobacillus and blood agar plates. The colony forming units was used to calculate the viability of the in-cultivated bacterial strains. The homogeneity of the colonies was confirmed by Gram staining.
- the fermented butter contains live bacteria.
- 1.2 x 10 of colony forming units (cfu) per ml was found. This number of live bacteria corresponds to 5% of cfu compared to fermented yogurt (cfu; 2.4 * 10 7 ).
- the composition of the fermented butter was also analysed by gas chromatography, where it was shown that close to 30% of fatty acids were unsaturated while 66% were saturated fatty acids (Table 1).
- Example 9 Effect of fermented yogurt or fermented butter on plasma lipid in five volunteers
- Fig 4 shows the serum-triglyceride levels of both groups (fermented yogurt and butter). Serum-triglyceride concentration was decreased with 18.4% (mean reduction) in the fermented yogurt group (IV and V), whereas the two persons in the fermented butter group showed an increase with 20% (mean increasing), after the 4 weeks period (II and III).
- Atherogenic Index [(total cholesterol - High-Density Lipoprotein cholesterol)/High-Density-Lipoprotein cholesterol] for both groups (butter and fermented yogurt groups) showed very small changes even after 4 weeks of consumption of butter (mean Al; from 2.97 to 3.02) or fermented yogurt (mean Al; from 2.13 to 2.05).
- the control showed an increase of triglyceride by 2% and almost no change in Al (Al; from 3.38 to 3.31), (Fig 5).
- fermented yogurt can lower the blood concentration of triglycerides and replacement of fermented butter, as an alternative to common butter, does not increase the serum triglycerides level significantly.
- Proximate composition fatty acids of fermented butter prepared from fermented yogurt.
- Palmitoleic acid 16 1 1,5
- Gadoleic acid 20 1 0,2
- the purity of the analysed butter was 94,8%.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
Abstract
L'invention concerne un produit laitier fermenté, tel qu'un yogourt, du beurre ou du fromage, comprenant des bactéries issues des espèces Lactobacillus et de la levure et possédant une teneur en galactose inférieure à 1,2 g/l, une teneur en lactose inférieure à 1,2 g/l et une teneur en acide lactique d'au moins 0,2 % en poids. L'invention concerne également un procédé en deux étapes permettant de produire un yogourt fermenté avec des bactéries Lactobacillus et de la levure, ainsi qu'une composition pharmaceutique ou probiotique renfermant le produit laitier fermenté, l'utilisation d'un produit laitier fermenté dans la production d'un médicament permettant de réduire les triglycérides plasmiques et les lipides, de retarder la mort cellulaire et la stéatose hépatique, notamment engendrée par la consommation d'alcool, de prévenir et de traiter l'athérosclérose et la coronaropathie, ainsi que des individus présentant des carences en lactase et en galactase. L'invention concerne enfin un produit alimentaire symbiotique ou fonctionnel renfermant le produit laitier fermenté.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201214 | 2002-04-23 | ||
SE0201214A SE0201214D0 (sv) | 2002-04-23 | 2002-04-23 | Multicultural fermented yoghurt |
PCT/SE2003/000632 WO2003090546A1 (fr) | 2002-04-23 | 2003-04-17 | Yogourt fermente a cultures multiples |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1503629A1 true EP1503629A1 (fr) | 2005-02-09 |
Family
ID=20287650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03721220A Withdrawn EP1503629A1 (fr) | 2002-04-23 | 2003-04-17 | Yogourt fermente a cultures multiples |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1503629A1 (fr) |
AU (1) | AU2003224556A1 (fr) |
SE (1) | SE0201214D0 (fr) |
WO (1) | WO2003090546A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110241046A (zh) * | 2019-06-26 | 2019-09-17 | 河北一然生物科技有限公司 | 一种能够缓解酒精性肝损伤的瑞士乳杆菌及应用 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029702B2 (en) | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
ITRM20040166A1 (it) | 2004-03-31 | 2004-06-30 | Alberto Cresci | Ceppi batterici lab con proprieta' probiotiche e composizioni che contengono gli stessi. |
US20070224285A1 (en) * | 2004-03-31 | 2007-09-27 | Calpis Co., Ltd | Agent for Preventing or Suppressing Hepatopathy and Functional Food for Preventing or Suppressing Hepatopathy |
WO2006012536A2 (fr) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Procedes et compositions pour le traitement de l'intolerance au lactose |
JP2009526528A (ja) * | 2006-02-13 | 2009-07-23 | マクニール ニュートリショナルズ,エル エル シー | 低ラクトース乳組成物及び関連方法 |
WO2010098822A1 (fr) | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Formulations prébiotiques et méthodes d'utilisation |
JP5804542B2 (ja) * | 2010-03-25 | 2015-11-04 | 雪印メグミルク株式会社 | 脂肪肝予防及び/又は抑制剤 |
WO2011137249A1 (fr) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Formulations prébiotiques et méthodes d'utilisation |
ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
ITRM20110477A1 (it) | 2011-09-09 | 2013-03-10 | Giovanni Mogna | Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell |
ITMI20111718A1 (it) | 2011-09-23 | 2013-03-24 | Probiotical Spa | Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali. |
ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
WO2015193845A1 (fr) * | 2014-06-19 | 2015-12-23 | Yoggies, S.R.O. | Yaourt acidophile |
WO2018142193A1 (fr) * | 2017-02-06 | 2018-08-09 | King Abdullah University Of Science And Technology | Procédé et système de production d'un produit alimentaire à base de yaourt |
CN108077440A (zh) * | 2018-02-02 | 2018-05-29 | 傲特更脑日布 | 一种黄油的提炼工艺 |
RU2708893C1 (ru) * | 2018-08-01 | 2019-12-12 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ улучшения липидного профиля за счет нормализации микробиома кишечника у лиц с ишемической болезнью сердца |
JP7258510B2 (ja) * | 2018-10-16 | 2023-04-17 | 株式会社カネカ | 発酵バターおよびその製造方法 |
WO2021195718A1 (fr) * | 2020-04-02 | 2021-10-07 | Ahtesh Fatah Bashir | Procédé de fermentation lactique |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5526827A (en) * | 1978-08-14 | 1980-02-26 | Shinkei Kashiyama | Mixed system of yeast-lactic acid bacteria and fermentation product |
DE3404474A1 (de) * | 1983-04-06 | 1984-10-11 | James Gorden Belleair Fla. Roberts | Verfahren zur herstellung eines mehrfach fermentierten molkereiproduktes |
DE60005104T2 (de) * | 1999-04-13 | 2004-08-19 | Sigma-Tau Healthscience S.P.A. | Diätzusatz aus fermentierte milchprodukte zur prävention von östeoporose |
-
2002
- 2002-04-23 SE SE0201214A patent/SE0201214D0/xx unknown
-
2003
- 2003-04-17 WO PCT/SE2003/000632 patent/WO2003090546A1/fr not_active Application Discontinuation
- 2003-04-17 AU AU2003224556A patent/AU2003224556A1/en not_active Abandoned
- 2003-04-17 EP EP03721220A patent/EP1503629A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO03090546A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110241046A (zh) * | 2019-06-26 | 2019-09-17 | 河北一然生物科技有限公司 | 一种能够缓解酒精性肝损伤的瑞士乳杆菌及应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2003224556A1 (en) | 2003-11-10 |
SE0201214D0 (sv) | 2002-04-23 |
WO2003090546A1 (fr) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003090546A1 (fr) | Yogourt fermente a cultures multiples | |
Yadav et al. | Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats | |
JP6782302B2 (ja) | クリステンセネラ菌(Christensenella intestinihominis)およびその使用 | |
KR101010914B1 (ko) | 항비만 및 뇌기능개선 관련 생리활성 기능을 가지는 프로바이오틱 유산균 락토바실러스 플란타늄 | |
AU2001252569B2 (en) | Fermented foods and process for producing the same | |
US20080286414A1 (en) | Drink Comprising a Combination of Fish Oil and Probiotics | |
Zommara et al. | Whey from cultured skim milk decreases serum cholesterol and increases antioxidant enzymes in liver and red blood cells in rats | |
Ngongang et al. | Effects of probiotic bacteria from yogurt on enzyme and serum cholesterol levels of experimentally induced hyperlipidemic Wistar Albino rats | |
US8758842B2 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
CN111543639A (zh) | 用以保护肝脏的含乳酸菌菌株的食品组合物以及医药组合物 | |
CN100356927C (zh) | 降胆固醇剂,胆酸次级产生抑制剂,以及食品和饮料 | |
KR101010913B1 (ko) | 항고혈압활성 락토바실러스 플란타룸 및 이를 포함하는 발효물 | |
US20140370047A1 (en) | Products and methods | |
Motawee | Biological effects of yoghurt with rosemary on injured liver rats | |
JP2001226277A (ja) | アルコール吸収代謝調整剤 | |
KR100769299B1 (ko) | 알코올 분해능이 있는 유산균 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제 | |
JP5818309B2 (ja) | 血中コレステロール低減剤 | |
WO2017141879A1 (fr) | Composition d'inhibiteur de la lipase pancréatique et procédé de production d'une composition d'inhibiteur de lipase pancréatique | |
JP4535554B2 (ja) | 2次胆汁酸産生抑制剤及び飲食品 | |
Seydim | Studies on fermentative, microbiological and biochemical properties of kefir and kefir grains | |
RU2225215C2 (ru) | Применение пропионовокислых бактерий для образования пропионовой кислоты и/или пропионатов в ободочной кишке | |
CN112538440B (zh) | 一种复合益生菌制剂及其制备方法和在促进人体乙醇代谢中的应用 | |
EP2986157B1 (fr) | Composition nutritionnelle fermentée avec inhibiteur de protéases de thiol | |
ODA et al. | Effects of skim milk and its fermented product by Lactobacillus acidophilus on plasma and liver lipid levels in diet-induced hypertriglyceridemic rats | |
Nur et al. | Hypocholesterolemic Effects of Maysghurt as A Functional Food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041119 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
17Q | First examination report despatched |
Effective date: 20060621 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061103 |